Ferrosa Therapeutics Raises $3.5M Seed to Advance Bispecific Antibody for Anemia of Inflammation

Anemia of inflammation doesn’t kick the door in. It lingers. Slows everything down. Drains performance in plain sight while bigger diagnoses take the spotlight. It’s the kind of problem that gets managed, tolerated, worked around… but rarely confronted head-on. Ferrosa Therapeutics AG just decided that’s not good enough.

Out of Basel, the city that treats biotech like a contact sport, Ferrosa Therapeutics AG secured $3.5M in seed funding, led by Forty51 Ventures, the same crew that doesn’t just invest in companies, they architect them. This isn’t spray and pray capital. This is deliberate. Built, not bet.

At the center of it, Martin Stern, MD, Co-Founder and CEO, alongside Co-Founders Sascha Oliver Bucher and Sara Nunez-Garcia, are betting on something the market has danced around for years. Not another patch. Not another workaround. A direct shot at the underlying biology driving anemia of inflammation.

Ferrosa’s angle is clean and a little dangerous in the best way. A first-in-class bispecific antibody designed to tackle two clinically validated pathways at once. Not one lever. Two. Because inflammation doesn’t play fair, and neither should the therapy. Iron homeostasis gets distorted, erythropoiesis gets suppressed, and most treatments politely try to manage symptoms. Ferrosa’s approach reads more like a correction than a compromise.

And here’s where it gets interesting. Chronic kidney disease, autoimmune disorders, oncology… different headlines, same underlying disruption. That’s the thread Ferrosa is pulling. One mechanism, multiple battlefields. If that holds, you’re not looking at a niche solution, you’re looking at a platform that knows how to travel.

The playbook, if we’re being honest, is hiding in plain sight. Start with a precise problem that’s been broadly tolerated for too long. Anchor it in real biology, not buzzwords. Bring in capital that understands formation, not just participation. Then move fast through preclinical proof like you’ve got something to prove… because you do.

Forty51 Ventures didn’t just fund a company here, they lit the fuse on a thesis: that fixing iron mismanagement at the source could unlock outcomes across multiple disease categories. That’s not a small claim. But then again, small claims don’t get built in Basel.

Now Ferrosa Therapeutics AG gets to do the hard part. Antibody generation. Engineering. In vivo proof. The kind of work that doesn’t care about headlines, only results. And if the science lands the way the idea suggests, this won’t stay a quiet problem for much longer.